

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-CB7FBB1D-2C4D-4A25-9038-591AC1DB6880\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M49150\\_03\\_01](https://doi.org/10.31003/USPNF_M49150_03_01)  
DOI Ref: 8a7n6

© 2025 USPC  
Do not distribute

## Meprobamate Tablets

### DEFINITION

Meprobamate Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of meprobamate ( $C_9H_{18}N_2O_4$ ).

### IDENTIFICATION

#### Change to read:

- A. **SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197K** (CN 1-MAY-2020)

**Sample:** A portion of finely powdered Tablets, equivalent to 800 mg of meprobamate

**Analysis:** To the *Sample* add 5 mL of dehydrated alcohol, and heat to just below boiling for about 5 min, with occasional swirling. Cool, and filter into 15 mL of solvent hexane. With the aid of suction, filter the crystals that form, and dry at 60°.

**Acceptance criteria:** The IR absorption spectrum of a potassium bromide dispersion (about 1 mg in 200 mg) from a portion of crystals obtained from the *Sample* exhibits maxima only at the same wavelengths as that of a similar preparation of [USP Meprobamate RS](#). If a difference appears, dissolve portions of both the *Sample* and the Reference Standard in acetone at a concentration of 8 mg/mL. Dilute 0.1-mL portions of the acetone solutions with 1 mL of *n*-heptane, and remove the solvents by evaporation under nitrogen at a temperature of about 30°. Dry the residues under vacuum at room temperature for 30 min, and repeat the test on the residues.

- B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### • PROCEDURE

**Mobile phase:** Acetonitrile and water (30:70)

**Phenacetin stock solution:** 125 µg/mL of phenacetin in acetonitrile

**Phenacetin solution:** 25 µg/mL of phenacetin prepared as follows from the *Phenacetin stock solution*. Pipet a suitable volume of *Phenacetin stock solution* into a volumetric flask. Add acetonitrile to fill 30% of the final flask volume, and dilute with water to volume.

**Standard solution:** 5 mg/mL of [USP Meprobamate RS](#) prepared as follows. Transfer a suitable amount of the Reference Standard to a suitable volumetric flask. Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume.

**System suitability solution:** 5 mg/mL of [USP Meprobamate RS](#) and 5 µg/mL of phenacetin prepared as follows. Dissolve a weighed amount of [USP Meprobamate RS](#), first in acetonitrile, using 20% final volume. Shake to dissolve. Add a suitable volume of *Phenacetin solution*, and dilute with water to volume.

**Sample solution:** Nominally equivalent to 5 mg/mL of meprobamate prepared as follows. Transfer an amount of meprobamate from a portion of finely powdered Tablets (NLT 20) to a suitable volumetric flask. Add acetonitrile to fill 30% of final volume, and shake to dissolve. Dilute with water to volume, and filter, discarding the first 10 mL of the filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 200 nm

**Column:** 3.9–4.6-mm × 25–30-cm; 5-µm packing L1

**Flow rate:** 1 mL/min

**Injection volume:** 20 µL

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for meprobamate and phenacetin are about 0.7 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 2.0 between the meprobamate and the phenacetin peaks, *System suitability solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of meprobamate ( $C_9H_{18}N_2O_4$ ) in the portion of Tablets taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

$r_u$  = peak response of meprobamate from the *Sample solution*

$r_s$  = peak response of meprobamate from the *Standard solution* $C_s$  = concentration of [USP Meprobamate RS](#) in the *Standard solution* (mg/mL) $C_u$  = nominal concentration of meprobamate in the *Sample solution* (mg/mL)**Acceptance criteria:** 90.0%–110.0%**PERFORMANCE TESTS**

- [Dissolution \(711\)](#).

**Procedure for a pooled sample****Medium:** Deaerated water; 900 mL**Apparatus 1:** 100 rpm**Time:** 30 min**Standard solution, System suitability solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.**Analysis**Calculate the percentage of the labeled amount of meprobamate ( $C_9H_{18}N_2O_4$ ) dissolved:

$$\text{Result} = (r_u/r_s) \times C_s \times V \times (1/L) \times 100$$

 $r_u$  = peak response from the *Sample solution* $r_s$  = peak response from the *Standard solution* $C_s$  = concentration of [USP Meprobamate RS](#) in the *Standard solution* (mg/mL) $V$  = volume of the *Medium*, 900 mL $L$  = label claim (mg/Tablet)**Acceptance criteria:** NLT 75% (Q) of the labeled amount of meprobamate ( $C_9H_{18}N_2O_4$ ) is dissolved.

- [Uniformity of Dosage Units \(905\)](#): Meet the requirements

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- [USP Reference Standards \(11\)](#).

[USP Meprobamate RS](#)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MEPROBAMATE TABLETS	<a href="#">Documentary Standards Support</a>	SM42020 Small Molecules 4

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 38(3)

**Current DocID: GUID-CB7FBB1D-2C4D-4A25-9038-591AC1DB6880\_3\_en-US****DOI: [https://doi.org/10.31003/USPNF\\_M49150\\_03\\_01](https://doi.org/10.31003/USPNF_M49150_03_01)****DOI ref: [8a7n6](#)**